Dutch startup's gene therapy offers new hope for rare disease treatment

2024-05-06 bio

Genethon’s innovative use of CRISPR in gene therapy marks a potential turning point for treating a rare genetic disorder.

A Leap Forward in Gene Therapy

Genethon, a biotech company based in Évry, Ile-de-France, France, has made significant strides in the field of gene therapy with their latest development. Utilizing the precision of CRISPR technology, they have designed a treatment that targets the root cause of a specific rare genetic disorder, Duchenne Muscular Dystrophy (DMD). This approach could revolutionize treatment protocols and offer new avenues for patients who have long awaited effective therapies.

Understanding the Impact

Duchenne Muscular Dystrophy is an inherited condition that causes muscle degeneration and weakness. Until now, treatment options have been limited and mostly focused on managing symptoms rather than treating the underlying genetic issue. Genethon’s gene therapy, known as GNT0004, aims to change this by delivering a functional version of the gene responsible for producing dystrophin, a protein essential for muscle integrity. The therapy’s promising initial results were presented by Professor Francesco Muntoni at the Myology 2024 international scientific congress in Paris.

Clinical Trial Insights

The clinical trial for GNT0004, sponsored by Genethon, commenced in 2021 and resumed in late 2022, following the resolution of a serious adverse event. It includes phases I/II/III with a dose escalation strategy, focusing on ambulant boys aged 6 to 10. To date, five patients have been treated, with results showing up to 85% of muscle fibers expressing microdystrophin and a significant decrease in CPK levels, indicating reduced muscle distress. The trial has received approval from French and UK health authorities and is now preparing for a pivotal phase with the European Medicines Agency.

The Path to Innovation

Genethon’s journey toward innovation is backed by its establishment in 1990 by AFM-TELETHON. With a team of over 180 experts, the nonprofit lab has become a pioneer in gene therapy for rare diseases. Genethon not only focuses on R&D but also on producing gene therapy products through Genethon BioProd, its manufacturing facility. The company’s dedication to treating rare disorders and the development of new therapeutic approaches exemplifies the potential impact of their work on patients’ lives.

The Future of Gene Therapy

The advancements made by Genethon signal a hopeful future for gene therapy applications. By addressing genetic disorders at their source, this technology promises to improve outcomes and quality of life for those affected by such conditions. As the field evolves and more therapies reach clinical stages, the potential for treating a wide range of diseases may soon become a reality, marking a transformative era in medicine.

Bronnen

gene therapy CRISPR